Richard Barron

1.7k total citations
55 papers, 1.3k citations indexed

About

Richard Barron is a scholar working on Oncology, Genetics and Surgery. According to data from OpenAlex, Richard Barron has authored 55 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 12 papers in Genetics and 11 papers in Surgery. Recurrent topics in Richard Barron's work include Neutropenia and Cancer Infections (33 papers), Blood disorders and treatments (11 papers) and Bone health and osteoporosis research (11 papers). Richard Barron is often cited by papers focused on Neutropenia and Cancer Infections (33 papers), Blood disorders and treatments (11 papers) and Bone health and osteoporosis research (11 papers). Richard Barron collaborates with scholars based in United States, Switzerland and Canada. Richard Barron's co-authors include Gary H. Lyman, Jason C. Legg, Xiaoyan Li, Lionel Pinto, Robert W. Dubois, Amber Trujillo Lalla, John H. Page, Lucie Kutikova, David Chandler and Onur Başer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Urology.

In The Last Decade

Richard Barron

52 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Barron United States 22 736 269 218 184 151 55 1.3k
Cristina Eller-Vainicher Italy 31 479 0.7× 235 0.9× 568 2.6× 1.0k 5.7× 28 0.2× 84 2.7k
Paul Ryan United Kingdom 20 249 0.3× 271 1.0× 244 1.1× 212 1.2× 15 0.1× 36 1.3k
Gianpaolo De Filippo Italy 22 336 0.5× 305 1.1× 191 0.9× 186 1.0× 16 0.1× 91 1.5k
Francesco Bertoldo Italy 33 876 1.2× 335 1.2× 1.2k 5.5× 257 1.4× 15 0.1× 90 2.6k
G. Kollerup Denmark 22 296 0.4× 115 0.4× 536 2.5× 136 0.7× 34 0.2× 43 1.7k
Hiroshi Naganuma Japan 19 314 0.4× 284 1.1× 77 0.4× 344 1.9× 25 0.2× 43 1.6k
J Muñoz-Gómez Spain 24 604 0.8× 116 0.4× 704 3.2× 328 1.8× 16 0.1× 58 1.9k
Elizabeth R. Volkmann United States 30 257 0.3× 114 0.4× 272 1.2× 297 1.6× 485 3.2× 121 3.3k
D. Wattie New Zealand 24 1.1k 1.5× 135 0.5× 1.1k 5.1× 221 1.2× 28 0.2× 37 2.1k
Robert Wong United States 30 130 0.2× 173 0.6× 244 1.1× 289 1.6× 123 0.8× 78 3.7k

Countries citing papers authored by Richard Barron

Since Specialization
Citations

This map shows the geographic impact of Richard Barron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Barron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Barron more than expected).

Fields of papers citing papers by Richard Barron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Barron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Barron. The network helps show where Richard Barron may publish in the future.

Co-authorship network of co-authors of Richard Barron

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Barron. A scholar is included among the top collaborators of Richard Barron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Barron. Richard Barron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yusuf, Akeem, et al.. (2020). Predictors of imminent risk of fracture in Medicare-enrolled men and women. Archives of Osteoporosis. 15(1). 120–120. 17 indexed citations
2.
Crawford, Jeffrey, Neelima Denduluri, Debra A. Patt, et al.. (2019). Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Supportive Care in Cancer. 28(2). 925–932. 40 indexed citations
3.
Guo, Haifeng, et al.. (2018). Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. Osteoporosis International. 29(11). 2409–2417. 20 indexed citations
4.
Kapinos, Kandice A., Shira H. Fischer, Andrew Mulcahy, Oliver Hayden, & Richard Barron. (2018). Medical Costs for Osteoporosis‐Related Fractures in High‐Risk Medicare Beneficiaries. Journal of the American Geriatrics Society. 66(12). 2298–2304. 11 indexed citations
5.
Kawatkar, Aniket A., Albert J. Farias, Chun Chao, et al.. (2017). Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Supportive Care in Cancer. 25(9). 2787–2795. 26 indexed citations
6.
O’Hanlon, Claire E, Anju Parthan, Shannon Cartier, et al.. (2017). A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture. Clinical Therapeutics. 39(7). 1276–1290. 13 indexed citations
7.
Fischer, Shira H., Kandice A. Kapinos, Andrew Mulcahy, et al.. (2017). Estimating the long-term functional burden of osteoporosis-related fractures. Osteoporosis International. 28(10). 2843–2851. 40 indexed citations
8.
Li, Xiaoyan, Michael Maschio, Guillermo Villa, et al.. (2016). Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 35(4). 425–438. 24 indexed citations
9.
Wang, Li, Richard Barron, Onur Başer, Wendy J. Langeberg, & David C. Dale. (2014). Cancer Chemotherapy Treatment Patterns and Febrile Neutropenia in the US Veterans Health Administration. Value in Health. 17(6). 739–743. 6 indexed citations
10.
Solomon, Daniel H., Erika Brown, David Chandler, et al.. (2014). Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis. Osteoporosis International. 25(9). 2255–2262. 1 indexed citations
11.
Li, Xiaoyan, Michael Maschio, Richard Barron, et al.. (2014). Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecologic Oncology. 133(3). 446–453. 8 indexed citations
12.
13.
14.
Henk, Henry J., Laura Becker, Hiangkiat Tan, et al.. (2012). Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. Journal of Medical Economics. 16(1). 160–168. 15 indexed citations
15.
Griffiths, Robert I., Richard Barron, Michelle Gleeson, et al.. (2011). Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer. PharmacoEconomics. 30(2). 103–118. 10 indexed citations
16.
Smith, Eve, Rohit Kumar, Richard Barron, & D. K. Bosman. (2010). An unusual cause of neonatal respiratory distress. BMJ Case Reports. 2010. bcr0520103022–bcr0520103022. 1 indexed citations
17.
Song, Xue, et al.. (2009). Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy. Journal of Medical Economics. 12(2). 154–163. 5 indexed citations
18.
Lyman, Gary H., Amber Trujillo Lalla, Richard Barron, & Robert W. Dubois. (2009). Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states. Clinical Therapeutics. 31(5). 1092–1104. 56 indexed citations
19.
Schurch, Brigitte, P. Denys, Chris M Kozma, et al.. (2007). Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence. European Urology. 52(3). 850–859. 74 indexed citations
20.
Barron, Richard, et al.. (1993). Natural Products and the Athlete: Facts and Folklore. Annals of Pharmacotherapy. 27(5). 607–615. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Eller-Vainicher Breakdown of academic impact, for papers by Paul Ryan Breakdown of academic impact, for papers by Gianpaolo De Filippo Breakdown of academic impact, for papers by Francesco Bertoldo Breakdown of academic impact, for papers by G. Kollerup Breakdown of academic impact, for papers by Hiroshi Naganuma Breakdown of academic impact, for papers by J Muñoz-Gómez Breakdown of academic impact, for papers by Elizabeth R. Volkmann Breakdown of academic impact, for papers by D. Wattie Breakdown of academic impact, for papers by Robert Wong
Rankless by CCL
2026